Trial Profile

A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors With PIK3CA or KRAS Mutations

Status: Not yet recruiting

Phase of Trial: Phase I/II

Latest Information Update: 05 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Canagliflozin (Primary) ; Serabelisib (Primary)
Indications Advanced breast cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors Petra Pharma

Most Recent Events

20 May 2020 Planned initiation date changed from 1 Jun 2020 to 1 Sep 2020.
17 Mar 2020 Planned initiation date changed from 15 Mar 2020 to 1 Jun 2020.
05 Feb 2020 Planned initiation date changed from 15 Jan 2020 to 15 Mar 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com